Answers are grounded in this paper and cite their sources.
Case analysis reveals significant drug interactions between clopidogrel and boosted antiretrovirals after coronary stenting, highlighting the need for pharmacist intervention.
Fictional caseA 75-year-old woman with HIV (virologically suppressed on darunavir/cobicistat 800/150 mg and emtricitabine/tenofovir alafenamide 200/10 mg daily) presented to her community pharmacy 1 week after hospital discharge.During a 4-day admission for an acute coronary syndrome, she underwent percutaneous coronary intervention (PCI) with placement of 2 drug-eluting stents to the left anterior descending coronary artery.Medications initiated in hospital included acetylsalicylic acid (ASA), clopidogrel, bisoprolol, ramipril, and atorvastatin.While filling her prescriptions, her pharmacist identified a drug-drug interaction (DDI) between clopidogrel and darunavir/cobicistat.
No takes yet. Share an insight, caveat, or question.
Ready et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: